AusCann Group Holdings Ltd Stock

Equities

AC8

AU000000AC89

Pharmaceuticals

Market Closed - Australian S.E. 02:10:35 2022-08-31 am EDT 5-day change 1st Jan Change
0.04 AUD -4.76% Intraday chart for AusCann Group Holdings Ltd -.--% -.--%
Sales 2022 2.04M 1.34M Sales 2023 1.55M 1.02M Capitalization 17.62M 11.6M
Net income 2022 -26M -17.11M Net income 2023 -10M -6.58M EV / Sales 2022 5.19 x
Net cash position 2022 5.72M 3.76M Net cash position 2023 7.3M 4.8M EV / Sales 2023 6.66 x
P/E ratio 2022
-0.62 x
P/E ratio 2023
-1.61 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 72.13%
More Fundamentals * Assessed data
Dynamic Chart
3 years
0.04
Extreme 0.035
0.12
5 years
0.04
Extreme 0.035
0.53
10 years
0.04
Extreme 0.035
1.86
More quotes
Managers TitleAgeSince
Director of Finance/CFO - 19-11-30
Members of the board TitleAgeSince
Director/Board Member 53 23-06-28
Director of Finance/CFO - 19-11-30
Chairman - Nov. 30
More insiders
AusCann Group Holdings Limited is an Australia-based company focused on the development and commercialization of cannabinoid-derived therapeutic products to address unmet needs for humans and animals within Australia and internationally. It has launched tetrahydrocannabinol and cannabidiol (THC/CBD) powder-based hard-shell capsules, based on the Company’s Neuvis platform, for the treatment of pain and related indications. Its products include CPAT-01, DermaCann and MicroMax. CPAT-01 is a liquid, oral veterinary medicine containing standardized tetrahydrocannabinol (THC) and cannabinoids (CBD) whole plant extracts in a proprietary ratio to target pain and inflammation in dogs. DermaCann is a CBD-derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. The product is a liquid oral oil formulation containing CBD in a patented combination with other bioactive lipids designed to target inflammation and immune modulation pathways.
More about the company